Prevalence of COVID-19 virus infection in asymptomatic volunteers in Baghdad city / Iraq during 2021
Keywords:
SARS-CoV-2, COVID-19, fluorescence immunoassay, IgG COVID, IgM COVID, laboratory parameters COVID, lab test COVIDAbstract
Background: From February April 2020, the COVID-19 pandemic has swept through more than 200 countries and infected more than 100 million individuals globally, posing an unprecedented threat to human health. There are currently no specific antiviral treatments for COVID-19 and vaccination programs, whilst promising, remain in their infancy. A key to restricting the pandemic is the ability to minimize human-human transmission and predict the infection status of the population in the face of emerging SARS-CoV-2 variants. Success in this area is dependent on the rapid detection of COVID-19 positive individuals with current/previous SARS-CoV-2 infection status. The 3 categories of tests used to detect current or past viral infection are molecular, serologic, and antigen-detection assays. Aims: This study aimed to evaluate the performance of the fluorescence LFIA Finecare TM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113) in Iraqi setting. Giving a look on the prevalence of Covid19 infection in Baghdad city is our second aim. Study design A retrospective study on 75 randomly selected serum samples collected between 10 and 15 April 2020 was performed. They were checked for Covid-19 specific IgG and IgM responses by FinCare™ rapid semi-automated kit. Two aims were put in examinations.
Downloads
References
Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda KJJocm. The role of antibody testing for SARS-CoV-2: is there one? 2020;58(8).
Van Walle I, Leitmeyer K, Broberg EKJE. Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020. 2021;26(45):2001675.
Dortet L, Ronat J-B, Vauloup-Fellous C, Langendorf C, Mendels D-A, Emeraud C, et al. Evaluating 10 commercially available SARS-CoV-2 rapid serological tests by use of the STARD (Standards for Reporting of Diagnostic Accuracy Studies) method. 2021;59(2):e02342-20
Mitani A, Horie T, Yokoyama R, Nakano Y, Hamada K, Inoue Y, et al. Interpretations of SARS CoV-2 IgM and IgG antibody titers in the seroepidemiological study of asymptomatic healthy volunteers. Journal of Infection and Chemotherapy. 2022;28(2):266-72.
Pakpour AH, Griffiths MD, Chang K-C, Chen Y-P, Kuo Y-J, Lin C-Y. Assessing the fear of COVID-19 among different populations: A response to Ransing et al.(2020). Brain, behavior, and immunity. 2020;89:524-5.
Almashhdani H, Alsaadie K. Corrosion Protection of Carbon Steel in seawater by alumina nanoparticles with poly (acrylic acid) as charging agent. Moroccan Journal of Chemistry. 2018 Apr 29;6(3):6-3.
Algaissi A, Alfaleh MA, Hala S, Abujamel TS, Alamri SS, Almahboub SA, et al. SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients. Scientific Reports. 2020;10(1):16561.
Dowlatshahi S, Shabani E, Abdekhodaie MJ. Serological assays and host antibody detection in coronavirus-related disease diagnosis. Arch Virol. 2021;166(3):715-31.
Almashhadani HA, Alshujery MK, Khalil M, Kadhem MM, Khadom AA. Corrosion inhibition behavior of expired diclofenac Sodium drug for Al 6061 alloy in aqueous media: Electrochemical, morphological, and theoretical investigations. Journal of Molecular Liquids. 2021 Dec 1;343:117656.
Bastos ML, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. bmj. 2020;370.
Nguyen D, Skelly D, Goonawardane N. A novel immunofluorescence assay for the rapid serological detection of SARS-CoV-2 infection. Viruses. 2021;13(5):747.
Nawfal R Hussein, Amer A Balatay, Ibrahim A Naqid, Shakir A Jamal, Narin A Rasheed, Alind N Ahmed, Reving S Salih, Ahmed S Mahdi, Sabeeha A Mansour, Shaveen Mahdi, Nashwan Ibrahim, Dildar H Musa, Zana SM. Saleem COVID-19 antibody seroprevalence in Duhok, Kurdistan Region, Iraq: A population-based study.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
